Mineralys Therapeutics (MLYS) to Post Earnings on Tuesday

Mineralys Therapeutics (NASDAQ:MLYS) is anticipated to issue its Q2 2026 results after the market closes on Tuesday, August 11th. Analysts expect the company to announce earnings of ($0.5486) per share for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:30 PM ET.

Mineralys Therapeutics (NASDAQ:MLYS) last released its earnings results on Wednesday, May 6th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.04. On average, analysts expect Mineralys Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Mineralys Therapeutics Trading Up 1.2%

MLYS stock traded up $0.32 during trading on Tuesday, reaching $26.10. 220,791 shares of the stock were exchanged, compared to its average volume of 1,311,261. Mineralys Therapeutics has a twelve month low of $12.59 and a twelve month high of $47.65. The company has a market capitalization of $2.15 billion, a P/E ratio of -12.70 and a beta of 0.68. The stock has a 50 day simple moving average of $26.79 and a 200-day simple moving average of $27.87.

Analysts Set New Price Targets

MLYS has been the topic of several recent research reports. Wall Street Zen lowered Mineralys Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Jefferies Financial Group reiterated a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Finally, TD Cowen assumed coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They issued a “buy” rating for the company. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $49.33.

Insider Buying and Selling

In other Mineralys Therapeutics news, Director Daphne Karydas sold 3,000 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the completion of the transaction, the director directly owned 6,200 shares in the company, valued at $155,000. This represents a 32.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $26.14, for a total value of $1,960,500.00. Following the transaction, the chief executive officer directly owned 614,321 shares of the company’s stock, valued at approximately $16,058,350.94. The trade was a 10.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 237,718 shares of company stock valued at $6,218,301. 18.94% of the stock is currently owned by insiders.

Institutional Trading of Mineralys Therapeutics

Hedge funds have recently modified their holdings of the company. RA Capital Management L.P. raised its stake in shares of Mineralys Therapeutics by 19.1% in the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock valued at $277,717,000 after acquiring an additional 1,176,470 shares during the last quarter. State Street Corp increased its holdings in Mineralys Therapeutics by 144.4% during the 4th quarter. State Street Corp now owns 3,184,999 shares of the company’s stock valued at $115,584,000 after purchasing an additional 1,881,976 shares in the last quarter. Caligan Partners LP increased its holdings in Mineralys Therapeutics by 37.4% during the 3rd quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock valued at $105,139,000 after purchasing an additional 755,302 shares in the last quarter. Franklin Resources Inc. raised its position in Mineralys Therapeutics by 0.3% in the 3rd quarter. Franklin Resources Inc. now owns 1,809,768 shares of the company’s stock valued at $68,626,000 after purchasing an additional 6,171 shares during the last quarter. Finally, Orbimed Advisors LLC raised its position in Mineralys Therapeutics by 93.3% in the 3rd quarter. Orbimed Advisors LLC now owns 1,469,494 shares of the company’s stock valued at $55,723,000 after purchasing an additional 709,143 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.